![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing aims to fund the clinical development of the company-lead product ANS-858, which is investigating in the early-stage clinical trial for the treatment of patients with alcohol use disorder.
Lead Product(s): ANS-858
Therapeutic Area: Psychiatry/Psychology Product Name: ANS-858
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: ABMRF
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing May 14, 2024
Details:
The funding will support the IND-enabling and early-stage development of selective, reversible, orally bioavailable ALDH2 inhibitor ANS-858 to treat alcohol use disorder.
Lead Product(s): ANS-858
Therapeutic Area: Psychiatry/Psychology Product Name: ANS-858
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Alcohol Abuse and Alcoholism
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 01, 2023